When was Enactuzumab launched in China?

Elranatamab is a new type of immunotherapy drug, especially used to treat multiple myeloma (MM) . This drug acts as a bispecific antibody that activates T cells by binding to B cell maturation antigen (BCMA) on cancer cells and CD3 on T cells, thereby directly killing myeloma cells. The drug's innovative nature and strong therapeutic potential make it an important advance in the treatment options for myeloma patients.

On April 12, 2025, Johnson & Johnson officially announced the launch of Elranatamab injection in China. This news marks the official entry of the drug in China, becoming a new option for the treatment of multiple myeloma. The launch of ernatumumab not only provides a new treatment option for multiple myeloma patients in China, but also further promotes the progress of anti-tumor immunotherapy.

Previously, ernetuzumab has been approved for clinical use in many countries, especially in the United States and European markets, and has been widely used in the treatment of multiple myeloma. For Chinese patients, the launch of eractuzumab not only enhances treatment options, but also provides more clinical research support, making the treatment effect more targeted and personalized.

The successful launch of Enactuzumab is also in line with the Chinese government's policy of increasing market supervision and accelerating approval of cancer drugs in recent years, especially in the field of anti-cancer drugs. China's drug regulatory authorities have paid great attention to the approval and marketing of this drug, which has brought more breakthroughs in domestic cancer treatment.

Although the launch of ernatumumab in China is of great significance, patients still need to carry out individualized treatment according to the doctor's recommendations when using it. The drug is mainly suitable for patients with multiple myeloma who have not responded adequately to other treatment options, especially those who have experienced multiple treatments and developed drug resistance.

Reference materials:https://www.drugs.com/mtm/elranatamab.html